Theriva Biologics, Inc. Sale of Stock, Consideration Received on Transaction
Theriva Biologics, Inc. (TOVX) reported Sale of Stock, Consideration Received on Transaction of $12.20 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-27.
Discontinued › Notes › Equity
us-gaap:SaleOfStockConsiderationReceivedOnTransaction · last filed 2019-02-27
- Theriva Biologics, Inc. sale of stock, consideration received on transaction for fiscal 2018 was $12.20M.
| Period end | Sale of Stock, Consideration Received on Transaction 12 month |
|---|---|
| 2018-12-31 | $12.20M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |